Anti-GD1a ganglioside antibodies in peripheral motor syndromes

Sex steroids affect the motivation to court mates, but less is known about how they influence motor movements associated with courtship behavior. Steroidal control of motor function may be especially important for species in which courtship requires superior strength, stamina, and neuromuscular coordination. Here we use the golden-collared manakin (Manacus vitellinus) to examine whether the neuromuscular circuitry that controls motoric aspects of courtship activity is sensitive to androgens. Males of this tropical species attract mates by rapidly jumping among branches in a courtship arena and using their wings to produce loud wing snaps. Testosterone activates this display via the androgen receptor (AR), and past work reveals that manakins injected with radio-labeled T (3H-T) accumulate radioactivity in the spinal cord. Thus, we used quantitative PCR to measure AR, estrogen receptor-α (ER-α) subtype, and aromatase (AROM) mRNA in spinal cords of male and female manakins and zebra finches. Expression of AR, but not ER-α or aromatase, was higher throughout the manakin spinal cord compared with the zebra finch. Next, we tested whether AR-expressing skeletal muscles are innervated by motor and sensory neurons that also express AR. To do this, we backfilled spinal neurons by injecting fluorescent tracers into select AR-sensitive wing and leg muscles of wild caught male and female manakins. We then removed these spinal cords and measured AR expression with in situ hybridization. Both sexes showed abundant AR mRNA in the cervical and lumbosacral spinal enlargements as well as in dorsal root ganglia attached to these enlargements. Together our findings suggest that androgens act widely on peripheral motor and sensory circuits in golden-collared manakins to influence wing snapping displays.

Download Full-text

Titration of serum anti-ganglioside antibodies in patients with chronic medular injury previous to treatment with GM1 ganglioside

Acta Ortopédica Brasileira ◽

10.1590/s1413-78522003000200001 ◽

2003 ◽

Vol 11 (2) ◽

pp. 69-71

Author(s):

Tarcísio Eloy Pessoa Barros Filho ◽

Ciro da Silva Filho

Keyword(s):

Spinal Cord ◽

Spinal Cord Injury ◽

Side Effects ◽

Spinal Cord Lesion ◽

Gm1 Ganglioside ◽

Chronic Spinal Cord Injury ◽

Cord Injury ◽

Ganglioside Antibodies ◽

Asialo Gm1 ◽

Cord Lesion

Anti-ganglioside serum titers were evaluated by ELISA in 150 patients with complete spinal cord lesion for 6 to 12 months (IgG monosialo GM1, IgM monosialo GM1, IgG asialo GM1, IgM asialo GM1, IgG disialo GD1b e IgM disialo GD1b) prior to treatment with GM1 100 mg/day i.m. Only 4 patients showed positive titers for anti-asialo-GM1 (IgM) antibodies . All patients were clinically examined during and after treatment. No important side effects were observed with GM1 therapy. These results suggest that GM1-ganglioside administration in patients with chronic spinal cord injury is safe.

Download Full-text

Regeneration of the peripheral motor nerves and myelin sheath following hyperglycemic induction and recovery

The FASEB Journal ◽

10.1096/fasebj.2021.35.s1.03720 ◽

2021 ◽

Vol 35 (S1) ◽

Author(s):

Sheridan Sargent

Keyword(s):

Myelin Sheath ◽

Motor Nerves ◽

Peripheral Motor

Download Full-text

Recurrent Guillain-Barré Syndrome with Anti-GT1a and Anti-GQ1b Ganglioside Antibodies

Journal of Clinical Neurology ◽

10.3988/jcn.2019.15.3.404 ◽

2019 ◽

Vol 15 (3) ◽

pp. 404

Author(s):

Jihyeon Hwang ◽

Ye-Ji Kwon ◽

Jong Kuk Kim ◽

Nam Jun Kim ◽

Seol-Hee Baek

Keyword(s):

Guillain Barre Syndrome ◽

Guillain Barré Syndrome ◽

Ganglioside Antibodies ◽

Guillain Barré ◽

Gq1b Ganglioside

Download Full-text

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study

Frontiers in Neurology ◽

10.3389/fneur.2021.758710 ◽

2021 ◽

Vol 12 ◽

Author(s):

Sepehr Mamoei ◽

Henrik Boye Jensen ◽

Andreas Kristian Pedersen ◽

Mikkel Karl Emil Nygaard ◽

Simon Fristed Eskildsen ◽

...

Keyword(s):

Multiple Sclerosis ◽

Longitudinal Study ◽

Transcranial Magnetic Stimulation ◽

Magnetic Stimulation ◽

Motor Evoked Potentials ◽

Step Test ◽

Conduction Time ◽

Lesion Load ◽

Clinical Trial Registration ◽

Peripheral Motor

Objective: Persons with multiple sclerosis (PwMS), already established as responders or non-responders to Fampridine treatment, were compared in terms of disability measures, physical and cognitive performance tests, neurophysiology, and magnetic resonance imaging (MRI) outcomes in a 1-year explorative longitudinal study.Materials and Methods: Data from a 1-year longitudinal study were analyzed. Examinations consisted of the timed 25-foot walk test (T25FW), six spot step test (SSST), nine-hole peg test (9-HPT), five times sit-to-stand test (5-STS), symbol digit modalities test (SDMT), transcranial magnetic stimulation (TMS) elicited motor evoked potentials (MEP) examining central motor conduction times (CMCT), peripheral motor conduction times (PMCT) and their amplitudes, electroneuronography (ENG) of the lower extremities, and brain structural MRI measures.Results: Forty-one responders and eight non-responders to Fampridine treatment were examined. There were no intergroup differences except for the PMCT, where non-responders had prolonged conduction times compared to responders to Fampridine. Six spot step test was associated with CMCT throughout the study. After 1 year, CMCT was further prolonged and cortical MEP amplitudes decreased in both groups, while PMCT and ENG did not change. Throughout the study, CMCT was associated with the expanded disability status scale (EDSS) and 12-item multiple sclerosis walking scale (MSWS-12), while SDMT was associated with number of T2-weighted lesions, lesion load, and lesion load normalized to brain volume.Conclusions: Peripheral motor conduction time is prolonged in non-responders to Fampridine when compared to responders. Transcranial magnetic stimulation-elicited MEPs and SDMT can be used as markers of disability progression and lesion activity visualized by MRI, respectively.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03401307.

Download Full-text